Acute myeloid leukaemia vaccine - AVAX Technologies

Drug Profile

Acute myeloid leukaemia vaccine - AVAX Technologies

Alternative Names: Acute myelogenous leukaemia vaccine - AVAX Technologies; L-Vax; Leukaemia vaccine - AVAX Technologies

Latest Information Update: 17 Mar 2008

Price : $50

At a glance

  • Originator AVAX Technologies
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 18 May 2000 Phase-II clinical trials for Acute myeloid leukaemia in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top